Suchergebnisse - "Portale, Anthony A"

PubPharm (106)

1

Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia : A Subgroup Analysis by Dose Level

enthalten in: The Journal of clinical endocrinology and metabolism | 2023

von Imel, E. | Glorieux, F. | Whyte, M. | +18

2

Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia

enthalten in: The Journal of clinical endocrinology and metabolism | 2022

von Weber, T. | Imel, E. | Carpenter, T. | +5

3

A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial

enthalten in: Pediatric nephrology (Berlin, Germany) | 2022

von Hanudel, M. | Laster, M. | Portale, A. | +21

4

Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia

enthalten in: The Journal of clinical endocrinology and metabolism | 2022

von Ward, L. | Glorieux, F. | Whyte, M. | +14

5

A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial

enthalten in: Pediatric nephrology | 2022

von Hanudel, M. | Laster, M. | Portale, A. | +21

6

A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial

enthalten in: Pediatric nephrology | 2022

von Hanudel, M. | Laster, M. | Portale, A. | +21

7

A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial

enthalten in: Pediatric nephrology | 2022

von Hanudel, M. | Laster, M. | Portale, A. | +21

8

Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia

enthalten in: The Journal of clinical endocrinology and metabolism | 2022

von Linglart, A. | Imel, E. | Whyte, M. | +10

9

Burosumab treatment in adults with X-linked hypophosphataemia : 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension

enthalten in: RMD open | 2021

von Briot, K. | Portale, A. | Brandi, M. | +27

10

Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia

enthalten in: Calcified tissue international | 2021

von Padidela, R. | Whyte, M. | Glorieux, F. | +21

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[11]